40.19
price down icon6.95%   -3.00
after-market After Hours: 40.19
loading
Cytokinetics Inc stock is traded at $40.19, with a volume of 1.69M. It is down -6.95% in the last 24 hours and down -12.63% over the past month.
See More
Previous Close:
$43.19
Open:
$42.33
24h Volume:
1.69M
Relative Volume:
1.13
Market Cap:
$5.06B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-7.6407
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-13.70%
1M Performance:
-12.63%
6M Performance:
-23.88%
1Y Performance:
-42.68%
1-Day Range:
Value
$39.81
$42.55
1-Week Range:
Value
$39.81
$46.07
52-Week Range:
Value
$39.81
$75.71

Cytokinetics Inc Stock (CYTK) Company Profile

Name
Name
Cytokinetics Inc
Name
Phone
(650) 624-3000
Name
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Employee
0
Name
Twitter
@Cytokinetics
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
CYTK's Discussions on Twitter

Compare CYTK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CYTK
Cytokinetics Inc
40.19 5.06B 18.47M -589.53M -399.80M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-07-25 Initiated Citigroup Buy
Jan-22-25 Initiated Stifel Buy
Nov-08-24 Initiated RBC Capital Mkts Outperform
Aug-13-24 Downgrade Goldman Buy → Neutral
Jan-24-24 Downgrade UBS Buy → Neutral
Jan-05-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-23 Initiated Goldman Buy
Nov-07-23 Initiated B. Riley Securities Buy
Aug-15-23 Initiated SVB Securities Outperform
Feb-17-23 Initiated BofA Securities Neutral
Dec-23-22 Reiterated Needham Buy
Dec-20-22 Initiated Truist Buy
Oct-11-22 Initiated UBS Buy
Jan-28-22 Initiated Goldman Buy
Dec-22-21 Initiated Oppenheimer Outperform
Dec-10-21 Initiated JP Morgan Overweight
Oct-07-21 Initiated Jefferies Buy
Mar-12-21 Initiated Wolfe Research Outperform
Feb-18-21 Initiated Barclays Overweight
Jan-20-21 Reiterated H.C. Wainwright Buy
Oct-29-20 Initiated Goldman Neutral
Jul-10-20 Initiated Raymond James Strong Buy
May-05-20 Initiated Mizuho Buy
Apr-09-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-21-18 Initiated Cantor Fitzgerald Overweight
Sep-10-18 Resumed Morgan Stanley Equal-Weight
Nov-22-17 Reiterated Morgan Stanley Overweight
Nov-22-17 Downgrade Needham Strong Buy → Buy
Nov-21-17 Reiterated H.C. Wainwright Buy
Jul-31-17 Initiated Morgan Stanley Overweight
Mar-08-17 Initiated Rodman & Renshaw Buy
Feb-06-17 Upgrade Needham Buy → Strong Buy
Dec-16-16 Initiated Cantor Fitzgerald Overweight
Jul-28-16 Reiterated Needham Buy
Nov-10-15 Reiterated FBR Capital Outperform
Nov-09-15 Reiterated ROTH Capital Buy
Jul-24-15 Reiterated MLV & Co Buy
Dec-31-14 Reiterated ROTH Capital Buy
Nov-04-14 Upgrade MLV & Co Hold → Buy
Apr-28-14 Reiterated Needham Buy
View All

Cytokinetics Inc Stock (CYTK) Latest News

pulisher
04:31 AM

Former Gilead legal star departs Cytokinetics as crucial FDA ruling approaches - The Business Journals

04:31 AM
pulisher
04:13 AM

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

04:13 AM
pulisher
04:00 AM

Cytokinetics Leadership Takes Center Stage at Elite Needham Healthcare Conference - Stock Titan

04:00 AM
pulisher
12:16 PM

Cytokinetics stock hits 52-week low at $40.49 amid market challenges - Investing.com UK

12:16 PM
pulisher
Mar 30, 2025

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy - Insider Monkey

Mar 30, 2025
pulisher
Mar 29, 2025

Cytokinetics Announces Data From Phase 1 Study of CK-4021586 - MarketScreener

Mar 29, 2025
pulisher
Mar 25, 2025

Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? - MSN

Mar 25, 2025
pulisher
Mar 20, 2025

Cytokinetics Launches EARTH-HCM: An Interactive Tool for Understanding Hypertrophic Cardiomyopathy and Improving Access to Care - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community - The Manila Times

Mar 20, 2025
pulisher
Mar 19, 2025

Cytokinetics EVP Malik sells $87,160 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Cytokinetics EVP Malik sells $87,160 in stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics announces inducement grants under Nasdaq listing rule 5635(C)(4) -March 18, 2025 at 04:15 pm EDT - MarketScreener

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics Strengthens Workforce: 13 New Hires Secure Strategic Equity Awards - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy on Cytokinetics, $120 target By Investing.com - Investing.com UK

Mar 18, 2025
pulisher
Mar 17, 2025

Cytokinetics Executives Engage in Multiple Stock Transactions - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness! - Smartkarma

Mar 17, 2025
pulisher
Mar 17, 2025

UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating -March 17, 2025 at 11:27 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual ... - NRToday.com

Mar 17, 2025
pulisher
Mar 15, 2025

Cytokinetics’ EVP sells $4,500 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 15, 2025

Cytokinetics EVP Andrew Callos sells $4,500 in stock By Investing.com - Investing.com UK

Mar 15, 2025
pulisher
Mar 14, 2025

Cytokinetics’ EVP sells $4,500 in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 13, 2025

Cytokinetics EVP Callos Andrew sells shares for $1.17 million By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Cytokinetics EVP Callos Andrew sells shares for $1.17 million - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 10, 2025

Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Why Have Cytokinetics Stocks Plummeted? - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics Completes Midcycle Review with FDA for Aficamten - TipRanks

Mar 10, 2025
pulisher
Mar 09, 2025

Robert I. Blum Sells 16,970 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

B. Riley Brokers Reduce Earnings Estimates for Cytokinetics - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Cytokinetics CEO Robert Blum sells shares worth $737,176 - Investing.com India

Mar 08, 2025
pulisher
Mar 08, 2025

Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook - sharewise

Mar 08, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Fady Ibraham sells $356,025 in stock By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Andrew Callos sells $144,565 in stock By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Andrew Callos sells $144,565 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Fady Ibraham sells $356,025 in stock - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics Executives Engage in Stock Transactions - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics CEO Robert Blum sells shares worth $737,176 By Investing.com - Investing.com UK

Mar 07, 2025
pulisher
Mar 07, 2025

Morgan Stanley raises Cytokinetics stock to Overweight, $67 target By Investing.com - Investing.com UK

Mar 07, 2025

Cytokinetics Inc Stock (CYTK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):